Rezolute gets an uplift from phase 3 tumor hyperinsulinism win ahead of FDA meeting

A phase 3 clinical trial of Rezolute’s ersodetug in tumor hyperinsulinism has hit its primary endpoint, boosting the biotech ahead of a potential filing for FDA approval in another indication.